PLoS ONE (Jan 2015)

Monoconjugation of Human Amylin with Methylpolyethyleneglycol.

  • Tháyna Sisnande,
  • Luiz Henrique Guerreiro,
  • Raquel R Braga,
  • Luana Jotha-Mattos,
  • Luiza C S Erthal,
  • Priscilla Tinoco,
  • Bruno M Ferreira,
  • Luís Maurício T R Lima

DOI
https://doi.org/10.1371/journal.pone.0138803
Journal volume & issue
Vol. 10, no. 10
p. e0138803

Abstract

Read online

Amylin is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. The therapeutic restoration of postprandial and basal amylin levels is highly desirable in diabetes mellitus. Protein conjugation with the biocompatible polymer polyethylene glycol (PEG) has been shown to extend the biological effects of biopharmaceuticals. We have designed a PEGylated human amylin by using the aminoreactive compound methoxylpolyethylene glycol succinimidyl carbonate (mPEGsc). The synthesis in organic solvent resulted in high yields of monoPEGylated human amylin, which showed large stability against aggregation, an 8 times increase in half-life in vivo compared to the non-conjugated amylin, and pharmacological activity as shown by modulation of cAMP production in MCF-7 cell line, decrease in glucagon and modulation of glycemia following subcutaneous administration in mice. Altogether these data reveal the potential use of PEGylated human amylin for the restoration of fasting amylin levels.